Skip to content

Preoperative Nutritional Support in Malnutritional Cancer Patients

Prospective Study of Preoperative Nutritional Support in Malnutritional Pancreatobiliary Cancer Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02626195
Enrollment
50
Registered
2015-12-10
Start date
2013-10-31
Completion date
2017-04-05
Last updated
2018-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary Cancer, Malnutrition, Pancreatic Cancer

Keywords

malnutrition, nutrition, nutritional support, hepatobiliary pancreatic cancer, hepatobiliary pancreatic surgery

Brief summary

Malnutrition patients are known to have more postoperative complications and mortality. And most of hepatobiliary-pancreatic cancer surgeries accompany high postoperative morbidity and mortality rate. Therefore for the malnourished patients anticipating major surgery, preoperative nutritional support is recommended according to the ASPEN (American society of parenteral and enteral nutrition) and ESPEN (European society of parenteral and enteral nutrition) guideline. However there is no prospective trial to prove the clinical impact of preoperative nutritional support for malnourished patients. The purpose of this study is to evaluate the clinical impact of preoperative nutritional support for malnourished cancer patients anticipating HBP surgery. Primary objective is to compare the complication rate and secondary object is to compare the quality of life, hospital stay and cost.

Detailed description

This is single arm study with historical comparison. The historical control group did not receiving nutritional support. In previous results show that about 25% complication rates. Complication rates are expected in the group receiving nutritional support is less than 10 % ( previous studies (NCCNCS-11-460)). For support group, preoperative nutritional support is given for 5 or more days preoperatively by nutritional support program. Nutritional support program is briefly described below. Interval: 5-10 days Contents: admission is required * Calories: 30-35Kg, via enteral or parenteral * Protein: 1.2-1.5g/Kg * Lipid : 1-1.5g/Kg * Mineral and vitamins supply * Blood glucose control * Daily monitoring by dietician and specialized nurse

Interventions

DIETARY_SUPPLEMENTnutritional support program

Nutritional support program is briefly described below. Interval: 5-10 days Contents: admission is required * Calories: 30-35Kg, via enteral or parenteral * Protein: 1.2-1.5g/Kg * Lipid : 1-1.5g/Kg * Mineral and vitamins supply * Blood glucose control * Daily monitoring by dietician and specialized nurse

Sponsors

Fresenius Kabi
CollaboratorINDUSTRY
National Cancer Center, Korea
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Subjects in anticipating major surgery of hepatobiliary pancreatic cancer 2. Patients diagnosed with malnutrition (at least more than one) 1. PG-SGA B or C 2. Weight loss \>10% within 6 month 3. BMI \<18.5 4. Serum Albumin \<3.0 3. Age less than 80 years old over 20 years old 4. Performance status (ECOG scale): 0-1 5. Adequate organ functions 1. Hb ≥7.0 g/dl 2. ANC ≥1,500/mm3 3. PLT ≥80,000/mm3 4. Liver function: AST/ALT ≤5×upper limit of normal 5. Creatinine ≤2.0 ULN

Exclusion criteria

1. Biopsy, drainage tube insertion, and other minor surgery 2. palliative surgery 3. Serious illness or medical conditions, as follows; 1. congestive heart failure (NYHA class III or IV) 2. unstable angina or myocardial infarction within the past 6 months, 3. significant arrhythmias requiring medication and conduction abnormality such as over 2nd degree AV block 4. uncontrolled hypertension 5. hepatic cirrhosis( ≥ Child class B) 6. interstitial pneumonia, pulmonary adenomatosis 7. psychiatric disorder that may interfere with and/or protocol compliance 8. unstable diabetes mellitus 9. uncontrolled ascites or pleural effusion 10. active infection 4. Pregnancy 5. Any patients judged by the investigator to be unfit to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
postoperative complicationat discharge. (expected the duration of hospital stay of postoperation is 4~6 weeks.)expected the duration of hospital stay of postoperation is 4\ 6 weeks.

Secondary

MeasureTime frameDescription
postoperative hospital stayexpected the duration of hospital stay of postoperation is 4~6 weeks.expected the duration of hospital stay of postoperation is 4\ 6 weeks.
quality of lifepreoperative, postoperative 14dayspreoperative, postoperative 14days
postoperative cost( + nutritional support cost)at discharge. (expected the duration of hospital stay of postoperation is 4~6 weeks.)expected the duration of hospital stay of postoperation is 4\ 6 weeks.

Other

MeasureTime frameDescription
immunologic change(CD4/CD8) after nutritional supportpreoperative, postoperative 14daysCD4/CD8, immunoglobulin G, M, A

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026